MEI Pharma (MEIP) Reports Q2 EPS of $0.32
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
MEI Pharma Reports Second Quarter Fiscal Year 2017 Results
February 8, 2017 8:30 AM ESTSAN DIEGO, Feb. 8, 2017 /PRNewswire/ --Â MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its second quarter ended December 31, 2016. The Company also highlighted recent clinical progress and outlined key milestones for the year ahead.
"We begin the new calendar year with all of the pieces we need to be successful," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "We now have a partner with the operational and financial capabilities to... More
